Oral monthly ibandronate in postmenopausal osteoporosis: Rationale and design of the mobile study

被引：0
|
作者：
Cooper, C
Delmas, PD
Coutant, K
Bonvoisin, B
Recker, RR
机构：
[1] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England
[2] Univ Lyon 1, F-69365 Lyon, France
[3] INSERM, Res Unit 403, Lyon, France
[4] Creighton Univ, Omaha, NE 68178 USA
[5] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
OSTEOPOROSIS INTERNATIONAL | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [41] Oral monthly ibandronate is well tolerated and efficacious in postmenopausal women: Results from the Monthly Oral Pilot Study (MOPS)
    Reginster, JY
    Dumont, E
    Wiese, C
    Wilson, K
    Schimmer, RC
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S105 - S106
  • [42] Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
    Miller, Paul D.
    Epstein, Sol
    Sedarati, Farhad
    Reginster, Jean-Yves
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 207 - 213
  • [43] Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis: 1-year results from mobile
    Reginster, JY
    Zikan, V
    Lorenc, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Stakkestad, JA
    BONE, 2005, 36 : S416 - S416
  • [44] Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE.
    Recker, RR
    Luckey, M
    Stakkestad, JA
    Civitelli, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [45] Once-monthly and daily oral ibandronate are similarly well tolerated in women with postmenopausal osteoporosis: 2-year results from mobile
    Luckey, M.
    Stepan, J.
    Kendler, D. L.
    Feldman, D.
    Lipschitz, S.
    Leigh, C.
    Burdeska, A.
    Hiltbrunner, V
    Morales-Torres, J.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S234
  • [46] Women prefer once-monthly oral ibandronate to weekly oral alendronate as postmenopausal osteoporosis treatment: Results of BALTO II
    Barrett-Connor, E.
    Bourgeois, P.
    Devas, V
    Masanauskaite, D.
    Minne, H.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S235
  • [47] Once-monthly ibandronate for postmenopausal osteoporosis: Review of a new dosing regimen
    Pyon, Eunice Y.
    CLINICAL THERAPEUTICS, 2006, 28 (04) : 475 - 490
  • [48] Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis.
    Miller, PD
    Kendler, DL
    Garnero, P
    Silverman, S
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Christiansen, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S284 - S284
  • [49] Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis
    Cooper, C
    Emkey, RD
    McDonald, RH
    Hawker, G
    Bianchi, G
    Wilson, K
    Schimmer, RC
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10): : 4609 - 4615
  • [50] Weekly dosing of oral ibandronate is effective in the prevention of postmenopausal osteoporosis
    Felsenberg, D
    Christiansen, C
    Cerwinski, E
    Burdeska, A
    Jonkanski, I
    Meinert, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S16 - S17
12345